United States

VistaGen Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19

Lead Product(s): Aloradine

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2020

Details:

VistaGen plans to submit its proposed protocol for a Phase 2 study of PH94B for treatment of adjustment disorder to the U.S. FDA through the FDA's new Coronavirus Treatment Acceleration Program.

CB Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

CB Therapeutics Enters into Collaboration Agreement with Cleveland Clinic for the Manufacture of Psilocybin

Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Cleveland Clinic

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 20, 2020

Details:

The MOU singed between the companies include, production of psilocybin and like molecules used in combination with psychotherapy for the treatment of depression and addiction, and two other molecule.